---
title: "LGsig: Gene-Expression Classifier Integrating Genetics to Predict Therapy Response in DLBCL"
id: "pubmed-42715516"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42715516"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42715516/"
doi: "10.1200/JCO-26-00451"
published_at: "2026-11-20T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# LGsig: Gene-Expression Classifier Integrating Genetics to Predict Therapy Response in DLBCL
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42715516
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42715516/)
- **DOI:** [10.1200/JCO-26-00451](https://doi.org/10.1200%2FJCO-26-00451)
- **Published At:** 2026-11-20T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Investigators developed **LGsig**, a gene expression–based classifier to assign every diffuse large B-cell lymphoma (**DLBCL**) into transcriptionally defined genetic subtypes. - Model training used paired genomic and transcriptomic data from N = 764 DLBCLs, restricted to cases with clear LymphGen classes: MCD, BN2, EZB, and ST2. - The team selected 294 genes by differential expression and implemented a nearest shrunken centroid classifier to create four LGsig labels: **MCDsig**, **BN2sig**, **ST2sig**, and **EZBsig**. - LGsig accurately recapitulated LymphGen (LG) subtype calls using RNA alone, extending subtype assignments to previously LG-unclassified tumors. - Reassigned LG-unclassified tumors showed transcriptional and clinical concordance with their matched LG counterparts, according to the authors’ analyses. - The classifier also redistributed LG A53 tumors (aneuploidy, **TP53** alterations) into more biologically relevant LGsig clusters based on transcriptional state. - For clinical translation, LGsig was applied to archival RNAseq from the POLARIX trial (N = 678) comparing pola-R-CHP versus R-CHOP. - Data indicated that LGsig improved the biomarker performance of LG in POLARIX, identifying subtypes that derived a survival advantage with pola-R-CHP across both LG-classified and previously unclassified cases. - The abstract reports enhancement of subtype-specific therapeutic stratification but the source did not provide detailed effect sizes, p-values, or survival statistics in the abstract. - The authors conclude LGsig integrates genetic and transcriptional dimensions to expand molecular classification in DLBCL and to better inform subtype-targeted therapeutic strategies.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42715516/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42715516%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42715516/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42715516/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42715516/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42715516/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42715516/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42715516/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42715516%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42715516%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42715516/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42715516/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42715516/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42715516/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Atypon full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--ascopubs.org-pb-assets-pubmed-JCO_125x30.png) Atypon ](https://ascopubs.org/doi/10.1200/JCO-26-00451?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed "See full text options at Atypon") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42715516/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42715516/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42715516/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42715516/#abstract) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42715516/#similar) * [Cited by](https://pubmed.ncbi.nlm.nih.gov/42715516/#citedby) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42715516/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42715516/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42715516/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42715516/#linkout) Title & authors Abstract Similar articles Cited by MeSH terms Substances Related information LinkOut - more resources J Clin Oncol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22J+Clin+Oncol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J+Clin+Oncol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42715516/) . 2026 Nov 20;44(33):3265-3277. doi: 10.1200/JCO-26-00451. Epub 2026 Sep 9. # LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma [Sravya Tumuluru](https://pubmed.ncbi.nlm.nih.gov/?term=Tumuluru+S&cauthor_id=42715516)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#full-view-affiliation-1 "Department of Medicine, Cornell University, New York, NY."), [Alan Cooper](https://pubmed.ncbi.nlm.nih.gov/?term=Cooper+A&cauthor_id=42715516)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#full-view-affiliation-2 "Yale University School of Medicine, New Haven, CT."), [Yanwen Jiang](https://pubmed.ncbi.nlm.nih.gov/?term=Jiang+Y&cauthor_id=42715516)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#full-view-affiliation-3 "Genentech, Inc, South San Francisco, CA."), [Connie Lee Batlevi](https://pubmed.ncbi.nlm.nih.gov/?term=Batlevi+CL&cauthor_id=42715516)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#full-view-affiliation-3 "Genentech, Inc, South San Francisco, CA."), [Will Harris](https://pubmed.ncbi.nlm.nih.gov/?term=Harris+W&cauthor_id=42715516)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#full-view-affiliation-3 "Genentech, Inc, South San Francisco, CA."), [Gilles Salles](https://pubmed.ncbi.nlm.nih.gov/?term=Salles+G&cauthor_id=42715516)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#full-view-affiliation-4 "Memorial Sloan Kettering Cancer Center, New York, NY."), [Marek Trneny](https://pubmed.ncbi.nlm.nih.gov/?term=Trneny+M&cauthor_id=42715516)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#full-view-affiliation-5 "First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic."), [Georg Lenz](https://pubmed.ncbi.nlm.nih.gov/?term=Lenz+G&cauthor_id=42715516)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#full-view-affiliation-6 "Department of Medicine, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany."), [Franck Morschhauser](https://pubmed.ncbi.nlm.nih.gov/?term=Morschhauser+F&cauthor_id=42715516)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#full-view-affiliation-7 "Department of Hematology, Hospital Claude Huriez, Lille, France."), [Fabrice Jardin](https://pubmed.ncbi.nlm.nih.gov/?term=Jardin+F&cauthor_id=42715516)[ 8 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#full-view-affiliation-8 "Department of Hematology, Centre Henri Becquerel, Rouen, France."), [Sandhya Balasubramanian](https://pubmed.ncbi.nlm.nih.gov/?term=Balasubramanian+S&cauthor_id=42715516)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#full-view-affiliation-3 "Genentech, Inc, South San Francisco, CA."), [Matthew Sugidono](https://pubmed.ncbi.nlm.nih.gov/?term=Sugidono+M&cauthor_id=42715516)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#full-view-affiliation-3 "Genentech, Inc, South San Francisco, CA."), [Alex F Herrera](https://pubmed.ncbi.nlm.nih.gov/?term=Herrera+AF&cauthor_id=42715516)[ 9 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#full-view-affiliation-9 "Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA."), [Justin Kline](https://pubmed.ncbi.nlm.nih.gov/?term=Kline+J&cauthor_id=42715516)[ 10 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#full-view-affiliation-10 "Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL."), [James K Godfrey](https://pubmed.ncbi.nlm.nih.gov/?term=Godfrey+JK&cauthor_id=42715516)[ 9 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#full-view-affiliation-9 "Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.") Affiliations Expand ### Affiliations * 1 Department of Medicine, Cornell University, New York, NY. * 2 Yale University School of Medicine, New Haven, CT. * 3 Genentech, Inc, South San Francisco, CA. * 4 Memorial Sloan Kettering Cancer Center, New York, NY. * 5 First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic. * 6 Department of Medicine, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany. * 7 Department of Hematology, Hospital Claude Huriez, Lille, France. * 8 Department of Hematology, Centre Henri Becquerel, Rouen, France. * 9 Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA. * 10 Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL. * PMID: **42715516** * DOI: [ 10.1200/JCO-26-00451 ](https://doi.org/10.1200/jco-26-00451) Item in Clipboard # LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma Sravya Tumuluru et al. J Clin Oncol. 2026. Show details Display options Display options Format Abstract PubMed PMID J Clin Oncol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22J+Clin+Oncol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J+Clin+Oncol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42715516/) . 2026 Nov 20;44(33):3265-3277. doi: 10.1200/JCO-26-00451. Epub 2026 Sep 9. ### Authors [Sravya Tumuluru](https://pubmed.ncbi.nlm.nih.gov/?term=Tumuluru+S&cauthor_id=42715516)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#short-view-affiliation-1 "Department of Medicine, Cornell University, New York, NY."), [Alan Cooper](https://pubmed.ncbi.nlm.nih.gov/?term=Cooper+A&cauthor_id=42715516)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#short-view-affiliation-2 "Yale University School of Medicine, New Haven, CT."), [Yanwen Jiang](https://pubmed.ncbi.nlm.nih.gov/?term=Jiang+Y&cauthor_id=42715516)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#short-view-affiliation-3 "Genentech, Inc, South San Francisco, CA."), [Connie Lee Batlevi](https://pubmed.ncbi.nlm.nih.gov/?term=Batlevi+CL&cauthor_id=42715516)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#short-view-affiliation-3 "Genentech, Inc, South San Francisco, CA."), [Will Harris](https://pubmed.ncbi.nlm.nih.gov/?term=Harris+W&cauthor_id=42715516)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#short-view-affiliation-3 "Genentech, Inc, South San Francisco, CA."), [Gilles Salles](https://pubmed.ncbi.nlm.nih.gov/?term=Salles+G&cauthor_id=42715516)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#short-view-affiliation-4 "Memorial Sloan Kettering Cancer Center, New York, NY."), [Marek Trneny](https://pubmed.ncbi.nlm.nih.gov/?term=Trneny+M&cauthor_id=42715516)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#short-view-affiliation-5 "First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic."), [Georg Lenz](https://pubmed.ncbi.nlm.nih.gov/?term=Lenz+G&cauthor_id=42715516)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#short-view-affiliation-6 "Department of Medicine, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany."), [Franck Morschhauser](https://pubmed.ncbi.nlm.nih.gov/?term=Morschhauser+F&cauthor_id=42715516)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#short-view-affiliation-7 "Department of Hematology, Hospital Claude Huriez, Lille, France."), [Fabrice Jardin](https://pubmed.ncbi.nlm.nih.gov/?term=Jardin+F&cauthor_id=42715516)[ 8 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#short-view-affiliation-8 "Department of Hematology, Centre Henri Becquerel, Rouen, France."), [Sandhya Balasubramanian](https://pubmed.ncbi.nlm.nih.gov/?term=Balasubramanian+S&cauthor_id=42715516)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#short-view-affiliation-3 "Genentech, Inc, South San Francisco, CA."), [Matthew Sugidono](https://pubmed.ncbi.nlm.nih.gov/?term=Sugidono+M&cauthor_id=42715516)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#short-view-affiliation-3 "Genentech, Inc, South San Francisco, CA."), [Alex F Herrera](https://pubmed.ncbi.nlm.nih.gov/?term=Herrera+AF&cauthor_id=42715516)[ 9 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#short-view-affiliation-9 "Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA."), [Justin Kline](https://pubmed.ncbi.nlm.nih.gov/?term=Kline+J&cauthor_id=42715516)[ 10 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#short-view-affiliation-10 "Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL."), [James K Godfrey](https://pubmed.ncbi.nlm.nih.gov/?term=Godfrey+JK&cauthor_id=42715516)[ 9 ](https://pubmed.ncbi.nlm.nih.gov/42715516/#short-view-affiliation-9 "Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.") ### Affiliations * 1 Department of Medicine, Cornell University, New York, NY. * 2 Yale University School of Medicine, New Haven, CT. * 3 Genentech, Inc, South San Francisco, CA. * 4 Memorial Sloan Kettering Cancer Center, New York, NY. * 5 First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic. * 6 Department of Medicine, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany. * 7 Department of Hematology, Hospital Claude Huriez, Lille, France. * 8 Department of Hematology, Centre Henri Becquerel, Rouen, France. * 9 Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA. * 10 Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL. * PMID: **42715516** * DOI: [ 10.1200/JCO-26-00451 ](https://doi.org/10.1200/jco-26-00451) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract **Purpose:** Genetic classification may advance precision medicine in diffuse large B-cell lymphoma (DLBCL), but existing tools like LymphGen (LG) are limited by complexity and incomplete classification and do not incorporate nongenetic features that affect disease biology and therapeutic outcomes. To address these limitations, we developed LG-sig (LGsig), a gene expression-based platform that classifies all DLBCLs and harmonizes both genetic and nongenetic dimensions of the disease. **Methods:** LGsig was built on the distinct subtype-specific gene expression signature of each LG class using paired genomic and transcriptomic data (National Cancer Institute/British Columbia Cancer Agency; N = 764). Model development was restricted to DLBCLs classified into _MYD88_ L265P and _CD79B_ mutations (MCD), _BCL6_ translocation and _NOTCH2_ mutations (BN2), _EZH2_ mutations and _BCL2_ translocation (EZB), or _SGK1_ and _TET2_ mutations (ST2). Gene features were selected by differential gene expression, with 294 genes being optimal for classification using a nearest shrunken centroid classifier. LGsig classifications were designated as _MCDsig_ , _BN2sig_ , _ST2sig_ , and _EZBsig_. The final model was applied to RNAseq from archival samples from the POLARIX trial (N = 678) to assess outcomes after polatuzumab vedotin-R-CHP (pola-R-CHP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for each LGsig subtype. **Results:** LGsig accurately identified LG subtypes using transcriptional data alone and extended assignments to all previously LG-unclassified cases. Importantly, LG-unclassified DLBCLs reassigned by LGsig mirrored the transcriptional and clinical features of their corresponding LG counterparts, supporting their reclassification. In addition, LGsig reassigned LG A53 DLBCLs, characterized by aneuploidy and _TP53_ alterations, into more biologically and therapeutically relevant LGsig clusters. Finally, LGsig improved the performance of LG as a biomarker in the POLARIX study, by identifying distinct DLBCL subtypes exhibiting a survival benefit with pola-R-CHP over R-CHOP in both LG-classified and LG-unclassified cases. **Conclusion:** LGsig expands molecular classification beyond current genetic classifiers in DLBCL by integrating both genetic and transcriptional dimensions of the disease to better inform subtype-specific therapeutic strategies. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Similar articles * [ Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel. ](https://pubmed.ncbi.nlm.nih.gov/41544233/) Yim J, Lee S, Kim S, Han B, Lim S, Song YK, Youk J, Bae JM, Koh J, Lee C, Kim YA, Paik JH, Kim TM, Yun H, Jeon YK.Yim J, et al.Blood Adv. 2026 Mar 24;10(6):1929-1942. doi: 10.1182/bloodadvances.2025017049.Blood Adv. 2026.PMID: 41544233Free PMC article. * [ Real-World Comparative Analysis of Polatuzumab Vedotin-Based Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone versus Standard Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Cohort Study. ](https://pubmed.ncbi.nlm.nih.gov/41264548/) Wang Z, Wei C, Shen KN, Cai H, Zhao D, Zhou D, Zhang W.Wang Z, et al.Oncology. 2026;104(7):759-771. doi: 10.1159/000
## Related Clinical Research

- [Sintilimab plus R-CHOP vs DA-EPOCH-R in PMBCL — article content unavailable on source page](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-sintilimab-plus-r-chop-versus-da-epoch-r-as-first-line-therapy-for-primary.md)
- [Selinexor plus R-CHOP Yields High Response in Newly Diagnosed Double/Triple‑Hit Lymphoma](https://medichelpline.com/clinical-feed/pubmed-42480213.md) (DOI: 10.1182/bloodadvances.2025018580)
- [Composite Follicular Lymphoma and Mantle Cell Lymphoma: Single-Case Diagnostic Report](https://medichelpline.com/clinical-feed/pubmed-42967635.md) (DOI: 10.3760/cma.j.cn112151-20260322-00195)
- [GAA as a Prognostic Biomarker and Therapeutic Target in Angioimmunoblastic T‑cell Lymphoma — Full](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-multi-omics-analysis-identifies-gaa-as-an-independent-poor-prognostic-biomarker.md)
- [Pan-B-Lineage Control of Antigen-Heterogeneous Lymphoma Using Adapter CAR-T Cells](https://medichelpline.com/clinical-feed/biorxiv-1-pan-b-lineage-targeting-with-adapter-car-t-cells-controls-antigen-heterogeneous.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.